Skip to main content
SpringerLink
Log in

Hodgkin-Lymphome

  • Chapter
Therapie innerer Krankheiten

  • 11 Accesses

Zusammenfassung

Das Hodgkin-Lymphom (Erstbeschreibung 1832 durch T. Hodgkin) ist eine bösartige lymphatische Systemerkrankung ungeklärter ätiologie, die unbehandelt im allgemeinen zum Tod führt, bei allerdings sehr unterschiedlich aggressivem Spontanverlauf. Die neoplastischen Zellen sind die malignen Hodgkin- und Reed-Sternberg-Zellen, die ihren Ursprung wahrscheinlich in unreifen hämatopoetischen Zellen haben [50]. Die Erkrankung entsteht meist in einem Lymphknoten der Halsregion und breitet sich zunächst lymphogen, in fortgeschrittenen Stadien aber auch hämatogen aus. Die Zahl der jährlichen Neuerkrankungen beträgt 2–4 pro 100 000 (zweigipflige Alterhäufigkeit bei 25 und 60 Jahren; Männer: Frauen 10:6). Klinisch wichtige Symptome sind neben Lymphknotenschwellungen, Fieber, Nachtschweiß, Gewichtsabnahme, Pruritus und (selten) Alkoholschmerz.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Bergsagel DE, Alison RE, Beau HA et al. (1982) Results of treating Hodgkin’s disease without a policy of laparotomy staging. Cancer Treat Rep 66:717

    PubMed  CAS  Google Scholar 

  2. Biti GP, Cimino G, Cartoni C et al. (1992) Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I–IIA Hodgkin’s diseas: Eight-year update of an Italian prospective randomized study. J Clin Oncol 10:378

    PubMed  CAS  Google Scholar 

  3. Blayney DW, Longo DL, Young RC et al. (1987) Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin’s desease. N Engl J Med 316:710

    Article  PubMed  CAS  Google Scholar 

  4. Bonadonna G, Valagussa P, Santoro A (1986) Alternating non-cross-resistant combination chemotherapy of MOPP in stage IV Hodgkin’s desease. A report of 8-year-results. Ann Intern Med 104:739

    Article  PubMed  CAS  Google Scholar 

  5. Connors JM, Klimo P, Adams G, Burns B, Cooper I et al. (1992) MOPP/ABV-Hybrid versus alternating MOPP/ABVD for advanced Hodgkin’s disease. Proc. Am Soc Clin Oncol 11:317

    Google Scholar 

  6. Cornbleet MA, Vitolo U, Ultmann JE, et al (1985) Pathologic stages IA and IIA Hodgkin’s desease: results of treatment with radiotherapy alone (1968–1980). J Clin Oncol 3:758

    PubMed  CAS  Google Scholar 

  7. Cosset JM, Henry-Amar M, Carde P, Clarke D, Le Bourgeois JP, Tubiana M (1984) The prognostic significance of large mediastinal masses in the treatment of Hodgkin’s disease. The experience of the institut Gustave-Roussy. Hematol Oncol 2:33

    Article  PubMed  CAS  Google Scholar 

  8. Desch EC, Lasla MR, Smith TJ, Hillner BE (1992) The optimal timing of autologous bone marrow transplantation in Hodgkin’s disease patients after a chemotherapy relapse. J Clin Oncol 10:200–209

    PubMed  CAS  Google Scholar 

  9. Desser RK, Golomb HM, Ultmann JE et al. (1977) Prognostic classification of Hodgkin’s disease in pathologic stage III, based on anatomic considerations. Blood 49:883

    PubMed  CAS  Google Scholar 

  10. Diehl LF, Perry DJ, Terebelo H et al. (1983) Radiation as salvage therapy for patients with Hodgkin’s disease relapsing after MOPP (mechlorethamine, vincristine, prednisone, and procarbazine) chemotherapy. Cancer Treat Rep 67:827

    PubMed  CAS  Google Scholar 

  11. Diehl V, Pfreundschuh M, Löffler M et al. (1989) Combined modality therapy for stages I–IIA massive mediastinal Hodgkin’s disease: a randomized trial of two double cycles of COPP + ABVD plus extended-field radiotherapy 40 Gy versus 20 Gy (bulky disease 40 Gy). Proc Am Soc Clin Oncol 8:253

    Google Scholar 

  12. Farah R, Ultmann J, Griem M et al. (1988) Extended Mantle radiation therapy for pathologic stage I and II Hodgkin’s disease. J Clin Oncol 6:1047

    PubMed  CAS  Google Scholar 

  13. Ferme C, Teillet F, D’Agay M-F et al. (1984) Comparison of six versus three courses of MOPP with clinical and surgical restaging. Cancer 54:2324–2329

    Article  PubMed  CAS  Google Scholar 

  14. Fox K, Lippmann SM, Cassady JR et al. (1987) Radiation therapy as salvage of Hodgkin’s disease following chemotherapy failure. J Clin Oncol 5:38

    PubMed  CAS  Google Scholar 

  15. Fuller LM, Hutchinson GB (1982) The colloborative trials for stage I and II Hodgkin’s disease. Cancer Treat Rep 66: 775

    PubMed  CAS  Google Scholar 

  16. Gause A, Pohl C, Tschierch A et al. (1991) Clinical significance of soluble CD30 antigen in the sera of patients with untreated Hodgkin’s disease. Blood 77:1983–1988

    PubMed  CAS  Google Scholar 

  17. Henkelmann GC, Hagemeister FB, Fuller LM (1988) Two cycles of MOPP and radiotherapy for stage III1A and stage III2B Hodgkin’s disease. J Clin Oncol 6:1293

    PubMed  CAS  Google Scholar 

  18. Henry-Amar M (1992) Second cancer after the treatment for Hodgkin’s disease: A report from the International Database on Hodgkin’s Disease. J Clin Oncol 3 [Suppl 4]: 117–128

    Google Scholar 

  19. Hoppe RT, Coleman CN, Cox RS, Rosenberg SA, Kaplan HS (1982) The management of stage I–II Hodgkin’s disease with irradiation alone or combined modality therapy: the Stanford experience. Blood 59:455

    PubMed  CAS  Google Scholar 

  20. Hoppe RT, Cox RS, Rosenberg SA, Kaplan HS (1982) Prognostic factors in pathologic stage III Hodgkin’s disease. Cancer Treat Rep 66:743

    PubMed  CAS  Google Scholar 

  21. Horning SJ, Hoppe RT, Hancock SL, Rosenberg SA (1988) Vinblastine, Bleomycin, and methotrexate: an effective adjuvant in favorable Hodgkin’s disease. J Clin Oncol 6:1822

    PubMed  CAS  Google Scholar 

  22. Kaplan HS (1980): Hodgkin’s disease, 2nd edn. Harvard Univ Press, Cambridge

    Google Scholar 

  23. Koziner B, Myers J, Redman J et al. (1986) Treatment of stages I and II Hodgkin’s disease with three different therapeutic modalities. Am J Med 80:1067

    Article  PubMed  CAS  Google Scholar 

  24. Levitt SH, Lee CKK, Bloomfield CD (1984) Radical radiation therapy in the treatment of laparotomy staged Hodgkin’s disease patients. Int J Radiat Oncol Biol. Phys 10:265

    Article  PubMed  CAS  Google Scholar 

  25. Löffler, M, Pfreundschuh M, Hasenclever D et al. (1988) Prognostic risk factors in advanced Hodgkin’s lymphoma. Report of the German Hodgkin Study Group. Blut 56:273

    Google Scholar 

  26. Longo DL, Young RC, DeVita VT et al. (1986) Twenty years of MOPP therapy for Hodgkin’s disease. J Clin Oncol 4: 1295

    PubMed  CAS  Google Scholar 

  27. Lukes RJ, Craver LF, Hall TC, Rappaport H, Rubin P (1986) Report of the nomenclature committee. Cancer Res 26:1311

    Google Scholar 

  28. Mauch P, Goffman T, Rosenthal DS et al. (1985) Stage III Hodgkin’s disease: improved survival with combined modality therapy as compared with radiation therapy alone. J Clin Oncol 3:1166

    PubMed  CAS  Google Scholar 

  29. Mauch P, Tarbell N, Skarin A et al. (1987) Wide-field radiation therapy alone or with chemotherapy for Hodgkin’s disease in relapse from combination chemotherapy. J Clin Oncol 5:544

    PubMed  CAS  Google Scholar 

  30. Mauch P, Tarbelli N, Weinstein H et al. (1988) Stage IA and IIA supradiaphragmatic Hodgkin’s disease: prognostic factors in surgically staged patients trated with mantle and paraaortic irradiation. J Clin Oncol 6:1576

    PubMed  CAS  Google Scholar 

  31. Mauch P, Larson D, Osteen R et al. (1990) Prognostic factors for positive surgical staging in patients with Hodgkin’s disease. J Clin Oncol 8:257–265

    PubMed  CAS  Google Scholar 

  32. McMillan A, Goldastone A (1991) What is the value of autologous bone marrow transplantation in the treatment of relapsed or resistant Hodgkin’s disease? Leukemia res 15: 237–243

    Article  CAS  Google Scholar 

  33. Pfreundschuh MG, Schoppe WD, Fuchs R, Pflüger K-H, Loeffler M, Diehl V (1987) Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin’s lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group. Cancer Treat Rep 71:1203

    PubMed  CAS  Google Scholar 

  34. Pfreundschuh M, Tirier C, Fuchs R, Wendt F, Löffler M, Gerhartz, Diehl V: (1987) Fast alternating chemotherapy with COPP/ABV/IMEP in patients with advanced Hodgkin’s disease. Proc ECCO 4:1052

    Google Scholar 

  35. Pfreundschuh M, Löffler M, Rühl U et al. (1988) Therapie der Hodgkin-Lymphome: Ergebnisse der Deutschen Hodgin-Studiengruppe. Onkologie 11:48

    Article  PubMed  CAS  Google Scholar 

  36. Pfreundschuh M, Diehl V (1989) Therapie rezidivierender Hogkin-Lymphome. I. Strahlentherapie und konventionelle Chemotherapie. Dtsch Wochenschr 114:880–884

    Article  CAS  Google Scholar 

  37. Pfreundschuh M, Diehl V (1989) Therapie rezidivierender Hodgkin-Lymphome II. Der Stellenwert der Knochenmarktransplantation. Dtsch Med Wochenschr.

    Google Scholar 

  38. Pfreundschuh M, Koch P, Kuse R et al. (1991) Dexa-BEAM as salvage therapy for COPP+ABVD refractory Hodgkin’s diseas: a phase II study of the German Hodgkin Study Group. Eur J Cancer 27 [Suppl 2]: 237

    Google Scholar 

  39. Pfreundschuh M, Lathan B, Loefller M, Hasenclever D, Rüffer U, Diehl V (1992) Future trials in Hodgkin’s disease. Report of a workshop. Annals Oncol 3 [Suppl 4]: 101–104

    Article  Google Scholar 

  40. Powlis WD, Mauch P, Goffman T, Goodman R (1987) Treatment of patients with „minimal“ stage IIIA Hodgkin’s disease. Int J Radiat Oncol Biol Phys 13:1437

    Article  PubMed  CAS  Google Scholar 

  41. Prosnitz LR, Curtis AM, Knowlton AH, Peters LM, Farber LR (1980) Supradiaphragmatic Hodgkin’s disease: significance of large mediastinal masses. Int J Radiat Oncol Biol Phys 6:809–813

    Article  PubMed  CAS  Google Scholar 

  42. Roach M, Kapp DS, Rosenberg SA et al. (1987) Radiotherapy with curative intent: An option in selected patients relapsing after chemotherapy for advanced Hodgkin’s disease. J Clin Oncol 5:550

    PubMed  Google Scholar 

  43. Rosenberg SA (1966) Report of the Committee in the staging of Hodgkin’s disease. Cancer Res 26:1310

    Google Scholar 

  44. Santoro A, Viviani S, Valagussa P (1986) CCNU, etoposide and prednimustine (CEP) in refractory Hodgkin’s disease. Sem Oncol 13 [Suppl 1]: 23

    CAS  Google Scholar 

  45. Santoro A, Bonadonna G, Valagussa P et al (1987) Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin’s disease: Superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 5:27

    PubMed  CAS  Google Scholar 

  46. Specht L, Nordentoft AM, Cold S, Clausen NT, Nissen NI (1987) Tumor burden in early stage Hodgkin’s disease: the single most important prognostic factor for outcome after radiotherapy. Br J Cancer 55:535

    Article  PubMed  CAS  Google Scholar 

  47. Straus DJ, Yahalom J, Gaynor J et al. (1992) Four cycles of chemotherapy and regional radiation therapy for clinical early-stage and intermediate-stage Hodgkin’s disease. Cancer 69:105

    Article  Google Scholar 

  48. Tubiana M, Henry-Amar M, Hayat M et al (1984) The EORTC treatment of early stages of Hodgkin’s disease: the role of radiotherapy. Int J Radiat Oncol Biol Phys 10:197

    Article  PubMed  CAS  Google Scholar 

  49. Tubiana M, Henry-Amar M, van der Werf-Messing B et al (1985) A multivariate analysis of prognostic factors in early stage Hodgkin’s disease. Int J Radiat Oncol Biol Phys 11: 23

    Article  PubMed  CAS  Google Scholar 

  50. Truemper L, Brady G, Bagg A et al. (1993) Single cell analysis of Hodgkin and Reed-Sternberg cells: Molecular heterogeneity of gene expression and p 53 mutations. Blood 81: 3097

    Google Scholar 

  51. Valagussa P, Santoro A, Fossati-Bellani F et al. (1987) Second acute leukemias and other malignancies following treatment for Hodgkin’s disease. J Clin Oncol 4:830

    Google Scholar 

  52. Willett CG, Linggood RM, Meyer J et al. (1987) Results of treatment of stage 3A Hodgkin’s disease. Cancer 59:27

    Article  PubMed  CAS  Google Scholar 

  53. Yahalom J, Ryu J, Straus DJ et al. (1991) Impact of adjuvant radiation of ther patterns of relapse and rate of relapse in advanced-stage Hodgkin’s disease treated with alternating chemotherapy combinations. J Clin Oncol 9:2193

    PubMed  CAS  Google Scholar 

  54. Zittoun R, Andebert A, Hoerni B et al. (1985) Extended versus involved fields irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin’s disease. J Clin Oncol 3:207

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. M. Preundschuh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V. Diehl
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medizinische Klinik II, Klinikum Großhadern, Marchioninistraße 15, D-81377, München, Deutschland

    Gustav Paumgartner

  2. Kastanienallee 14, D-82049, Großhesselohe, Deutschland

    Gerhard Riecker

Rights and permissions

Reprints and permissions

Copyright information

© 1995 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Preundschuh, M., Diehl, V. (1995). Hodgkin-Lymphome. In: Paumgartner, G., Riecker, G. (eds) Therapie innerer Krankheiten. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-10479-8_45

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-10479-8_45

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-10480-4

  • Online ISBN: 978-3-662-10479-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation